Having completed its second Phase 3 trial of MDMA-AT for PTSD in 2022, MAPS will almost certainly be the first psychedelic drug developer to file a New Drug Application with the FDA in 2023. COMPASS Pathways’ ambitious Phase 3 program, meanwhile, is a milestone for both COMPASS Pathways and psychedelic drug development writ large, representing the most mature clinical investigation of a classical…
